AU2014227807B2 - Pharmaceutical composition comprising an AMPK activator and a serotonergic agent and methods of use thereof - Google Patents

Pharmaceutical composition comprising an AMPK activator and a serotonergic agent and methods of use thereof Download PDF

Info

Publication number
AU2014227807B2
AU2014227807B2 AU2014227807A AU2014227807A AU2014227807B2 AU 2014227807 B2 AU2014227807 B2 AU 2014227807B2 AU 2014227807 A AU2014227807 A AU 2014227807A AU 2014227807 A AU2014227807 A AU 2014227807A AU 2014227807 B2 AU2014227807 B2 AU 2014227807B2
Authority
AU
Australia
Prior art keywords
piperidin
acetamide
agent
fluorobenzyl
serotonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014227807A
Other languages
English (en)
Other versions
AU2014227807A1 (en
Inventor
Chien-Hung Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALS MOUNTAIN LLC
Original Assignee
ALS MOUNTAIN LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014227807(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ALS MOUNTAIN LLC filed Critical ALS MOUNTAIN LLC
Publication of AU2014227807A1 publication Critical patent/AU2014227807A1/en
Application granted granted Critical
Publication of AU2014227807B2 publication Critical patent/AU2014227807B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
AU2014227807A 2013-03-15 2014-03-14 Pharmaceutical composition comprising an AMPK activator and a serotonergic agent and methods of use thereof Ceased AU2014227807B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793407P 2013-03-15 2013-03-15
US61/793,407 2013-03-15
PCT/US2014/028413 WO2014144130A2 (en) 2013-03-15 2014-03-14 Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2014227807A1 AU2014227807A1 (en) 2015-11-05
AU2014227807B2 true AU2014227807B2 (en) 2018-03-08

Family

ID=51538303

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014227807A Ceased AU2014227807B2 (en) 2013-03-15 2014-03-14 Pharmaceutical composition comprising an AMPK activator and a serotonergic agent and methods of use thereof

Country Status (16)

Country Link
US (1) US20140350064A1 (enExample)
EP (1) EP2983473A4 (enExample)
JP (1) JP2016513734A (enExample)
KR (1) KR20160005341A (enExample)
CN (1) CN105636438A (enExample)
AR (1) AR095631A1 (enExample)
AU (1) AU2014227807B2 (enExample)
BR (1) BR112015023922A2 (enExample)
CA (1) CA2909633A1 (enExample)
CL (1) CL2015002680A1 (enExample)
HK (1) HK1222297A1 (enExample)
IL (1) IL241587B (enExample)
MX (1) MX2015012760A (enExample)
RU (1) RU2015143438A (enExample)
TW (1) TW201444552A (enExample)
WO (1) WO2014144130A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180071269A1 (en) * 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
ES2567105B1 (es) * 2014-09-19 2017-02-10 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
US10463649B2 (en) 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
WO2017018752A1 (ko) * 2015-07-29 2017-02-02 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
KR101663543B1 (ko) * 2015-07-29 2016-10-07 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
WO2017023833A1 (en) * 2015-08-01 2017-02-09 Petti Stephen J Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature
CN105541665A (zh) * 2016-02-18 2016-05-04 江苏大学 一种抗肿瘤药物化合物及制备方法和应用
KR101838625B1 (ko) * 2016-09-20 2018-03-14 김브라이언 아디포넥틴 수용체에 대한 작용제 펩타이드
AU2017340403B2 (en) 2016-10-05 2022-03-17 The United States as Represented by the Department of Veterans Affairs Small molecule AMPK activators
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN107252425A (zh) * 2017-07-12 2017-10-17 上海华堇生物技术有限责任公司 去氢延胡索素的药物用途
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
CN108159044A (zh) * 2018-02-26 2018-06-15 华中科技大学 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CN108997172B (zh) * 2018-08-08 2020-12-15 中国人民解放军总医院 抗肿瘤化合物
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN109771424B (zh) * 2019-03-11 2021-03-16 马慧 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
AU2020345766A1 (en) 2019-09-10 2022-03-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for increasing level of phosphorylated AMPK protein
CN110559298A (zh) * 2019-10-28 2019-12-13 中国药科大学 一种天然化合物Egenine用于制备抗肾纤维化药物的用途
AU2020372682A1 (en) 2019-10-31 2022-06-09 Jd Bioscience Inc. Tricyclic compound and pharmaceutical use thereof
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
CN114728933B (zh) * 2020-07-22 2023-06-16 山东绿叶制药有限公司 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用
CN117015378A (zh) * 2021-03-10 2023-11-07 杰那医疗公司 哺乳动物slc6a19功能的小分子抑制剂
IL305262A (en) 2021-03-10 2023-10-01 Jnana Therapeutics Inc Small molecule inhibitors of mammalian SLC6A19 function
AU2022309017A1 (en) 2021-07-07 2024-01-25 Terran Biosciences Inc. N,n-dimethyltryptamine and related psychedlics and uses thereof
WO2023086962A1 (en) 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
US20250032450A1 (en) * 2021-11-18 2025-01-30 Cybin UK Ltd. Injectable and inhalable formulations
TW202440068A (zh) * 2022-12-05 2024-10-16 美商恩維達醫療公司以恩維達生物科學公司之名營業 用於治療搔癢之諾卡酮（ｎｏｏｔｋａｔｏｎｅ）

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120232003A1 (en) * 2009-03-13 2012-09-13 Takahashi Joseph S Compositions and methods for diabetes treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
WO2006001278A1 (ja) * 2004-06-28 2006-01-05 Kao Corporation Ａｍｐｋ活性化剤
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US7754700B2 (en) * 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
SG178716A1 (en) * 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
US20120183600A1 (en) * 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
US8486922B2 (en) * 2010-04-28 2013-07-16 Chien-Hung Chen Composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120232003A1 (en) * 2009-03-13 2012-09-13 Takahashi Joseph S Compositions and methods for diabetes treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANISIMOV V N ET AL, "Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo", CELL CYCLE (2010), Vol. 9, No. 1, Pages 188 - 197 *
T A MAN 'CHEVA ET AL, "Melatonin and Metformin Inhibit Skin Carcinogenesis and Lipid Peroxidation Induced by Benz(a)pyrene in Female Mice", BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2011), Vol. 151, No. 26, pages 339 - 342 *

Also Published As

Publication number Publication date
EP2983473A4 (en) 2016-11-23
JP2016513734A (ja) 2016-05-16
MX2015012760A (es) 2016-06-17
WO2014144130A3 (en) 2015-02-05
TW201444552A (zh) 2014-12-01
KR20160005341A (ko) 2016-01-14
HK1222297A1 (zh) 2017-06-30
AU2014227807A1 (en) 2015-11-05
WO2014144130A2 (en) 2014-09-18
CN105636438A (zh) 2016-06-01
AR095631A1 (es) 2015-10-28
CA2909633A1 (en) 2014-09-18
US20140350064A1 (en) 2014-11-27
BR112015023922A2 (pt) 2017-07-18
CL2015002680A1 (es) 2016-09-02
EP2983473A2 (en) 2016-02-17
IL241587B (en) 2019-01-31
RU2015143438A (ru) 2017-04-21

Similar Documents

Publication Publication Date Title
US20140350064A1 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
US20120183600A1 (en) Novel composition for treating metabolic syndrome and other conditions
AU2007234382B2 (en) Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
CN101272782B (zh) 作为生长激素促分泌受体的ghrelin类似物配体的新颖的三唑衍生物
CN105579044A (zh) 双脱水半乳糖醇及其类似物与衍生物用于治疗复发性恶性神经胶瘤或进行性继发脑瘤的用途
SK13952002A3 (sk) Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén
TW201544107A (zh) Ｈｓｐ９０抑制劑之組合
US20090105282A1 (en) Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using pde 5 inhibitors
JP2010516689A (ja) メタボリック症候群治療用の新規組成物
US20090042905A1 (en) Triazole derivatives as ligands of g-protein coupled receptors
CN101466365A (zh) 增强认知功能的方法
JPH02121935A (ja) 大脳卒中の治療のための薬剤
US20040029972A1 (en) Combination treatment for depression
JP2017119702A (ja) ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤
CN110636862A (zh) 用于治疗乳腺癌的组合疗法
AU2010235917A1 (en) Combination of organic compounds
AU2015328044A1 (en) Pharmaceutical composition comprising Aspirin, Metformin, and Serotonin with non-ionic surfactant
Saxena et al. Therapeutic possibilities with serotonergic drugs
DUGOVIC et al. Turnhoutseweg 30
CN1933835A (zh) 控制食物摄取的方法
CN101198253A (zh) 治疗癌症的组合、方法和组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired